Prediction of Treatment Outcome in Bipolar Disorder: When Can We Expect Clinical Relevance?

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023752%3A_____%2F25%3A43921530" target="_blank" >RIV/00023752:_____/25:43921530 - isvavai.cz</a>

Výsledek na webu

<a href="https://www.sciencedirect.com/science/article/pii/S0006322325001039?via%3Dihub" target="_blank" >https://www.sciencedirect.com/science/article/pii/S0006322325001039?via%3Dihub</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.biopsych.2025.02.005" target="_blank" >10.1016/j.biopsych.2025.02.005</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Prediction of Treatment Outcome in Bipolar Disorder: When Can We Expect Clinical Relevance?

Popis výsledku v původním jazyce

Long-term pharmacological treatment is the cornerstone of the management of bipolar disorder (BD). Clinicians typically select mood-stabilizing medications from among several options through trial and error. This process could be optimized by using robust predictors of treatment response. We review clinical features and biological markers studied in relation to outcome of long-term treatment of BD. To date, the literature focuses mostly on lithium and to a lesser extent on the anticonvulsants valproate and lamotrigine. The most promising results show association of lithium response with certain clinical features (episodic clinical course and absence of rapid cycling, low rates of comorbid conditions, family history of BD and lithium response) as well as low polygenic risk for schizophrenia and major depression. The clinical application of these findings remains limited, however, due to heterogeneity of the illness as well as unanswered questions about specificity of the effects of different medications.

Název v anglickém jazyce

Prediction of Treatment Outcome in Bipolar Disorder: When Can We Expect Clinical Relevance?

Popis výsledku anglicky

Long-term pharmacological treatment is the cornerstone of the management of bipolar disorder (BD). Clinicians typically select mood-stabilizing medications from among several options through trial and error. This process could be optimized by using robust predictors of treatment response. We review clinical features and biological markers studied in relation to outcome of long-term treatment of BD. To date, the literature focuses mostly on lithium and to a lesser extent on the anticonvulsants valproate and lamotrigine. The most promising results show association of lithium response with certain clinical features (episodic clinical course and absence of rapid cycling, low rates of comorbid conditions, family history of BD and lithium response) as well as low polygenic risk for schizophrenia and major depression. The clinical application of these findings remains limited, however, due to heterogeneity of the illness as well as unanswered questions about specificity of the effects of different medications.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30215 - Psychiatry

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2025

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Biological Psychiatry

ISSN

0006-3223

e-ISSN

1873-2402

Svazek periodika

98

Číslo periodika v rámci svazku

4

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

8

Strana od-do

285-292

Kód UT WoS článku

001578013300006

EID výsledku v databázi Scopus

2-s2.0-105002027092